IENF
-
Presentation
- Similar to the clinical peripheral neuropathy in man, the degeneration of intra-epidermal nerve fibers (IENF) can be monitored and quantified in various animal models of peripheral neuropathy.
NEUROFIT implements this translational test to evaluate the neuroprotective effect of drug therapy as a treatment for peripheral neuropathy but also to study the peripheral neuropathy as a result of a potential side-effect of a drug treatment.
- Similar to the clinical peripheral neuropathy in man, the degeneration of intra-epidermal nerve fibers (IENF) can be monitored and quantified in various animal models of peripheral neuropathy.
-
Compound testing
Neuroprotective drugs are usually tested in this model but other treatments could also be considered.
Please feel free to contact us to discuss the feasibility of your study.
-
Endpoints
IENF density
-
Black arrows indicate IENF
White arrowheads indicate dermal nerve bundles -
NEUROFIT offers on fee-for-service basis the quantification IENF in rat skin biopsies as a robust and cost-effective assay to evaluate:
the peripheral neuropathy as a result of a potential side-effect of a drug treatment (safety profiling of drug candidates) the neuroprotective effect of drug therapy as a treatment for peripheral neuropathy (preclinical efficacy testing)
Many drugs and toxins have been reported to induce peripheral neuropathies. Often, this adverse effect requires the withdrawal of the treatment.
Example of drugs: Chemotherapy agents (Paclitaxel, Vincristine, Cisplatin ...) Anti-HIV therapy (Nucleoside analog reverse transcriptase inhibitors) Antibiotic (Metronidazole)
-
Degeneration of intraepidermal nerve fibers (IENF) is also found in neuropathies associated with metabolic (diabetes), infectious (HIV/AIDS) and autoimmune (vasculitis) diseases. -
Degeneration of IENF is a sensitive clinical marker to evaluate the severity of peripheral neuropathies. Loss of IENF is observed in both symptomatic or asymptomatic peripheral neuropathies.
-
Paclitaxel-related neuropathy
Dideoxycytidine-related neuropathyDrugs Rat strain Treatment regimen Timepoints IENF density (n/mm) sem n p-value (t-test) Placebo (Saline) Dideoxycytidine (50 mg/kg; i.v.) Sprague-Dawley
Sprague-Dawley1 single i.v Day 8
Day 880.4
56.02.1
46
5
0.01Placebo (Saline) Paclitaxel (2 mg/kg; i.p.) Sprague-Dawley
Sprague-Dawley4 injections every other day Day 31
Day 3176.03
58.71
73
5
0.0202
You could also be interested in
-
CMAP
Compound muscle action potential (CMAP) consist in stimulating a nerve fiber and monitoring the response in the muscle.
Hot plate
The Hot Plate test consists in a thermal pain measurement.
Paw pressure
The paw pressure test consists in applying a uniformly increasing mechanical pressure on the animal paw.
-
SNCV
Sensory nerve conduction velocity is used in the diagnosis of nerve damage or nerve dysfunction.
Streptozotocin : peripheral neuropathies
Diabetic neuropathy can be studied in rat following streptozotocin administration which induces a rapid and persistent hyperglycaemia.
Streptozotocin : neuropatic pain
Painful diabetic neuropathy can be studied in rat within few weeks following streptozotocin administration.